Compliance & Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical, legal, regulatory, or professional advice. The compounds discussed are research chemicals not approved for human consumption by the US FDA, European Medicines Agency (EMA), UK MHRA, Australian TGA, Health Canada, or any other major regulatory authority. They are sold strictly for laboratory research use. WolveStack does not employ medical staff, does not diagnose, treat, or prescribe, and makes no health claims under FTC, UK ASA, EU MDR/UCPD, or AU TGA standards. Always consult a licensed healthcare professional in your jurisdiction before considering any peptide protocol. This site contains affiliate links (FTC 2023 endorsement guidelines compliant); we may earn a commission on qualifying purchases at no additional cost to you. Some compounds discussed are on the WADA prohibited list — competitive athletes should verify current status with their governing body before any research use. Use of research chemicals may be illegal in your jurisdiction.
Editorial policy
Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.
Medical Disclaimer
For informational and educational purposes only. Not FDA-approved for human use. Consult a licensed healthcare professional. See full disclaimer.
BPC-157 is researched for gastritis through its core mechanism of gastric protection and mucosal healing, with particular strength in NSAID-induced gastritis. Preclinical evidence shows BPC-157 reduces gastric inflammation, accelerates ulcer healing, protects against acid damage, and restores gastric mucosal integrity. A typical protocol involves 200-500 mcg daily for 4-8 weeks, often combined with acid reduction therapy.
What Is Gastritis? Understanding Gastric Inflammation
Gastritis—inflammation of the stomach lining—causes pain, nausea, bloating, and bleeding. Causes include H. pylori infection, NSAIDs, stress, alcohol, bile reflux, and autoimmune attack. The underlying pathology involves excessive acid production, reduced protective mucus layer, and mucosal inflammation.
Standard treatment includes H. pylori eradication (antibiotics), proton pump inhibitors (PPIs), and H2 blockers. These suppress acid but don't actively heal the gastric lining. BPC-157's mechanism—directly protecting and healing gastric tissue—addresses a different problem.
BPC-157's Core Mechanism: Gastric Mucosal Protection
BPC-157 was originally discovered and named for its gastric protection in animal models. The peptide works through multiple mechanisms critical for gastric health:
- Mucus Layer Enhancement: Upregulates gastric mucus synthesis, strengthening the barrier against acid
- Anti-Inflammatory Action: Reduces pro-inflammatory cytokines (TNF-α, IL-6) that drive gastric inflammation
- Acid Regulation: Modulates stomach acid production—reducing excess, preserving physiologic levels
- Angiogenesis: Promotes blood vessel formation for improved mucosal oxygenation and nutrient delivery
- Epithelial Cell Healing: Accelerates gastric epithelial cell regeneration and ulcer closure
- Protective Prostaglandins: Enhances prostaglandin synthesis, which protects the gastric lining
These mechanisms directly reverse the pathology of gastritis—not just suppressing acid, but actively restoring gastric health.
NSAID-Induced Gastritis: BPC-157's Signature Indication
Chronic NSAID use (ibuprofen, naproxen, aspirin) damages gastric mucosa by inhibiting protective prostaglandins and increasing acid damage. BPC-157 specifically protects against NSAID-induced gastritis in preclinical models by restoring prostaglandins and enhancing mucosal healing.
For chronic pain patients requiring NSAIDs, BPC-157 may be the optimal gastroprotection strategy—replacing PPIs with a tissue-healing approach. BPC-157 prevents ulcer formation while PPIs only suppress acid.
Protocol for NSAID-users: 250-500 mcg daily subcutaneous, taken simultaneously with NSAID therapy. Continue 4-8 weeks beyond NSAID cessation for complete healing.
H. Pylori-Associated Gastritis and BPC-157
H. pylori infection causes chronic gastritis, ulcers, and increases gastric cancer risk. Standard treatment is triple or quadruple antibiotic therapy, which effectively eradicates the bacteria. However, even after successful eradication, mucosal inflammation and damage persist.
BPC-157 could serve as post-eradication therapy: after antibiotics resolve H. pylori, BPC-157 supports the healing of damaged gastric mucosa, potentially reducing relapse risk and accelerating symptomatic recovery. This is speculative (no human trials exist) but mechanistically sound.
Protocol: After completing H. pylori eradication therapy, initiate BPC-157 at 300-500 mcg daily for 4-8 weeks to optimize mucosal healing.
Stress-Induced Gastritis and Functional Dyspepsia
Psychological stress triggers gastric inflammation and excessive acid production. BPC-157's anti-inflammatory properties and mucosal protection may help stress-induced gastritis.
Additionally, BPC-157's documented effects on the nervous system and stress response (through CNS mechanisms) might address the stress-component of stress-gastritis holistically. This multi-level approach—mucosal healing + stress system modulation—is unique to BPC-157.
BPC-157 Protocol for Acute vs. Chronic Gastritis
Acute Gastritis (food reaction, temporary irritation): High-dose BPC-157 (500 mcg daily) for 2-4 weeks often resolves symptoms quickly. Combined with dietary modification (bland food, reduced alcohol/caffeine), acute cases typically resolve in 2-4 weeks.
Chronic Gastritis (H. pylori, NSAID use, autoimmune): Lower maintenance dosing (250-300 mcg daily) for 8-12+ weeks ensures sustained healing. Chronic cases require longer cycles; relapse is common if therapy stops prematurely.
Recurrent Gastritis: Maintenance dosing (200-250 mcg, 3x weekly) between cycles may prevent recurrence in susceptible individuals.
BPC-157 vs. PPIs: Complementary vs. Competitive?
Proton pump inhibitors (omeprazole, esomeprazole) are first-line gastritis treatment. They suppress acid effectively but don't heal the gastric lining or address mucosal inflammation. BPC-157 directly heals tissue.
Some practitioners use both: PPI for acute symptom relief + acid suppression, BPC-157 for mucosal healing. Others transition from PPI to BPC-157 once acute symptoms resolve. No head-to-head comparison exists in humans.
Long-term PPI use carries risks (nutrient malabsorption, increased infections, altered gut bacteria). BPC-157 offers a healing-focused alternative with potentially fewer long-term risks.
Combination Therapy: Optimizing Gastritis Recovery
BPC-157's best results emerge with supportive care:
- Dietary Modification: Eliminate triggers (spicy, acidic, fatty foods; alcohol; caffeine); support with bland, protein-rich diet
- Probiotics: Support healthy stomach and intestinal bacteria; may enhance BPC-157 effect
- Bone Broth or Collagen: Provide amino acids (glutamine, glycine) that support epithelial repair
- Stress Management: Meditation, exercise, counseling; reduce stress-driven acid production
- Sleep Optimization: Adequate sleep supports mucosal healing
- Anti-inflammatory Supplements: Turmeric (curcumin), slippery elm, licorice may complement BPC-157
Timeline: When Gastritis Improves on BPC-157
Gastritis improvement typically follows this trajectory:
- Days 1-7: Possible initial worsening (healing flare); stabilization by day 7
- Weeks 1-2: Pain reduction; improved tolerance of food
- Weeks 2-4: Significant symptom improvement; reduced bloating, improved digestion
- Weeks 4-8: Sustained healing; ability to reintroduce previously irritating foods
Acute cases may resolve in 2-4 weeks; chronic cases require 8+ weeks for full healing.
Trusted Research-Grade Sources
Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).
Particle Peptides
Independently HPLC-tested, transparent COAs, comprehensive product range.
Browse Particle Peptides →Limitless Life Nootropics
Premium research peptides with strong customer support and verified purity.
Browse Limitless Life →FAQs: BPC-157 for Gastritis
Should I stop my PPI to use BPC-157?
No. If you're on a PPI, continue it while starting BPC-157. Some practitioners recommend tapering PPI dose gradually once BPC-157 is working, but never stop abruptly. Acid rebound can occur. Work with your doctor on coordinated transitions.
Can BPC-157 replace a PPI long-term?
Possibly, for mild gastritis. For severe cases or high acid production, PPIs may be necessary for acute control while BPC-157 supports healing. Eventually, if gastritis resolves completely, you might transition fully to BPC-157. Individualize under medical guidance.
How long does a BPC-157 gastritis cycle last?
Typically 4-8 weeks. Acute cases often resolve in 4 weeks; chronic gastritis requires 8+ weeks. Some practitioners recommend 6-8 weeks as standard, with reassessment at 4 weeks.
Can BPC-157 prevent NSAID-induced gastritis?
Preclinical evidence suggests yes. If you require chronic NSAIDs, taking BPC-157 simultaneously may prevent ulcer formation and mucosal damage. This is an interesting preventive application, though human trials don't exist yet.
Is oral BPC-157 effective for gastritis?
Oral peptides face stomach acid degradation. While some preclinical gastritis studies used oral administration, injectable BPC-157 is more reliable. If you prefer oral, discuss with a practitioner about special delivery formulations.
What about H. pylori? Does BPC-157 treat it?
No. BPC-157 does not kill H. pylori; antibiotics are required. However, BPC-157 can complement antibiotic treatment by supporting mucosal healing during eradication and accelerating recovery post-treatment.